Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...

Agco has a stable balance sheet with net/debt EBITDA of approximately 2.0 times and investment-grade credit ratings. The company has been formed via many acquisitions, and this continues as it pursues ...

The "Global TROP2 Antibody Market & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In what marks a significant leap forward in precision oncology, the TROP2 ...